Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic : changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era
COVID-19 pandemic revolutionized the way in which cancer patients are treated worldwide. Regarding neuro-oncological patients, usually considered frail and with lower life-expectancy in respect to other oncological patients, the international scientific community had to urgently reorganize the treatment approach in order to minimize the risk of in-hospital contagious. For GBM patients, adjuvant treatments have been evaluated with even much more attention with regard to the expected efficacy. As a consequence, an hypofractioned radiotherapy regimen has been preferred in order to reduce the daily hospital accesses and, especially in pMGMT unmethylated patients, chemotherapy with Temozolomide was avoided. Here, we made a comprehensive evaluation of the neurooncological community suggestions regarding GBM treatment in the pre-vaccine era of COVID-19 pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Acta bio-medica : Atenei Parmensis - 93(2022), 3 vom: 01. Juli, Seite e2022067 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Internò, Valeria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 04.07.2022 Date Revised 23.08.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.23750/abm.v93i3.12452 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34296562X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34296562X | ||
| 003 | DE-627 | ||
| 005 | 20231226015324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23750/abm.v93i3.12452 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM34296562X | ||
| 035 | |a (NLM)35775774 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Internò, Valeria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic |b changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.07.2022 | ||
| 500 | |a Date Revised 23.08.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a COVID-19 pandemic revolutionized the way in which cancer patients are treated worldwide. Regarding neuro-oncological patients, usually considered frail and with lower life-expectancy in respect to other oncological patients, the international scientific community had to urgently reorganize the treatment approach in order to minimize the risk of in-hospital contagious. For GBM patients, adjuvant treatments have been evaluated with even much more attention with regard to the expected efficacy. As a consequence, an hypofractioned radiotherapy regimen has been preferred in order to reduce the daily hospital accesses and, especially in pMGMT unmethylated patients, chemotherapy with Temozolomide was avoided. Here, we made a comprehensive evaluation of the neurooncological community suggestions regarding GBM treatment in the pre-vaccine era of COVID-19 pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Dacarbazine |2 NLM | |
| 650 | 7 | |a 7GR28W0FJI |2 NLM | |
| 700 | 1 | |a Rudà, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Sergi, Maria Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Soffietti, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Porta, Camillo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta bio-medica : Atenei Parmensis |d 2002 |g 93(2022), 3 vom: 01. Juli, Seite e2022067 |w (DE-627)NLM12090733X |x 2531-6745 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2022 |g number:3 |g day:01 |g month:07 |g pages:e2022067 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.23750/abm.v93i3.12452 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2022 |e 3 |b 01 |c 07 |h e2022067 | ||